European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Blood

Volumn 122, Issue 6, 2013, Pages 872-884

  Baccarani, Michele ^a   Deininger, Michael W ^b   Rosti, Gianantonio ^a   Hochhaus, Andreas ^c   Soverini, Simona ^a   Apperley, Jane F ^d   Cervantes, Francisco ^e   Clark, Richard E ^f   Cortes, Jorge E ^g   Guilhot, François ^h   Hjorth Hansen, Henrik ⁱ   Hughes, Timothy P ^j   Kantarjian, Hagop M ^g   Kim, Dong Wook ^k   Larson, Richard A ^l   Lipton, Jeffrey H ^m   Mahon, François Xavier ⁿ   Martinelli, Giovanni ^a   Mayer, Jiri ^o   Müller, Martin C ^p   Niederwieser, Dietger ^q   Pane, Fabrizio ^r   Radich, Jerald P ^s   Rousselot, Philippe ^t   Saglio, Giuseppe ^u   Saußele, Susanne ^p   Schiffer, Charles ^v   Silver, Richard ^w   Simonsson, Bengt ^x   Steegmann, Juan Luis ^y   Goldman, John M ^d   Hehlmann, Rüdiger ^p   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF UTAH   (United States)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF BARCELONA   (Spain)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITÉ DE POITIERS   (France)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k The Catholic University of Korea   (South Korea)

^l UNIVERSITY OF CHICAGO   (United States)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ BORDEAUX UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^p UNIVERSITY OF HEIDELBERG   (Germany)

^q UNIVERSITY OF LEIPZIG   (Germany)

^r UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^s Fred Hutchinson Cancer Research Center   (United States)

^t LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^u UNIVERSITY OF TURIN   (Italy)

^v WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w WEILL CORNELL MEDICAL COLLEGE   (United States)

^x UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^y HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL1 PROTEIN; BOSUTINIB; BUSULFAN; CYTARABINE; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PONATINIB; RADOTINIB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTERY DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CYTOGENETICS; DISEASE SURVEILLANCE; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; IC 50; LOW DRUG DOSE; LUNG COMPLICATION; MEDICATION COMPLIANCE; MONOTHERAPY; MYELOABLATIVE CONDITIONING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; EUROPE; METABOLISM; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZAMIDES; EUROPE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; THIAZOLES; TREATMENT OUTCOME;

EID: 84881298446     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-501569     Document Type: Review

References (169)

1. Hehlmann R, Hochhaus A, Baccarani M. on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet. 2007; 370(9584): 342-350.
2. Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011; 29(18): 2514-2520.
3. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012; 119(9): 1981-1987.
4. Baccarani M, Saglio G, Goldman J., et al.; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6): 1809-1820. (Pubitemid 44394987)
5. Baccarani M, Cortes J, Pane F., et al.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35): 6041-6051.
6. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukemia BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC. 2008: 32-37
7. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63(4): 789-799. (Pubitemid 14141296)
8. Hasford J, Pfirrmann M, Hehlmann R., et al.; Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90(11): 850-858. (Pubitemid 28280552)
9. Hasford J, Baccarani M, Hoffmann V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011; 118(3): 686-692.
10. Testoni N, Marzocchi G, Luatti S., et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood. 2009; 114(24): 4939-4943.
11. Hughes T, Deininger M, Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108(1): 28-37. (Pubitemid 43990609)
12. Branford S, Fletcher L, Cross N.C., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112(8): 3330-3338.
13. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009; 23(11): 1957-1963.
14. Cross NCP, White HE, Müller MC, Saglio G., Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26(10): 2172-2175.
15. O'Brien S.G., Guilhot F, Larson R.A., et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11): 994-1004. (Pubitemid 36302244)
16. Hughes TP, Kaeda J, Branford S., et al.; International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349(15): 1423-1432. (Pubitemid 37211057)
17. Druker BJ, Guilhot F, O'Brien SG, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408-2417. (Pubitemid 44903745)
18. Hochhaus A, O'Brien SG, Guilhot F, et al.; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6): 1054-1061.
19. Deininger M, O'Brien S, Guilhot F, et al. International randomized study of interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. [abstract] Blood. 2009; 114(22):[Abstract 1126]
20. Cortes JE, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11(9): 3425-3432. (Pubitemid 40627896)
21. de Lavallade H., Apperley JF, Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20): 3358-3363.
22. Marin D, Milojkovic D, Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112(12): 4437-4444.
23. Hughes TP, Branford S, White D.L., et al.; Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008; 112(10): 3965-3973.
24. Baccarani M, Rosti G, Castagnetti F., et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009; 113(19): 4497-4504.
25. Cortes JE, Kantarjian HM, Goldberg S.L., et al.; Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009; 27(28): 4754-4759.
26. Cortes JE, Baccarani M, Guilhot F., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28(3): 424-430.
27. Cervantes F, López-Garrido P, Montero MI, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica. 2010; 95(8): 1317-1324.
28. Preudhomme C, Guilhot J, Nicolini F.E., et al.; SPIRIT Investigators; France Intergroupe des Leucémies Myélöides Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363(26): 2511-2521.
29. Gugliotta G, Castagnetti F, Palandri F., et al.; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011; 117(21): 5591-5599.
30. Faber E, Mužík J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry. Eur J Haematol. 2011; 87(2): 157-168.
31. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011; 29(12): 1634-1642.
32. Kim DW, Goh HG, Kim S.H., Choi SY, Park SH, Jang EJ, Kim DW. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol. 2012; 96(1): 47-57.
33. Radich JP, Kopecky KJ, Appelbaum F.R., et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012; 120(19): 3898-3905.
34. Cortes JE, Kim DW, Kantarjian H.M., et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012; 30(28): 3486-3492.
35. Saglio G, Kim DW, Issaragrisil S, et al.; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2251-2259.
36. Kantarjian HM, Hochhaus A, Saglio G., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12(9): 841-851.
37. Larson RA, Hochhaus A, Hughes T.P., et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10): 2197-2203.
38. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2260-2270.
39. Kantarjian HM, Shah NP, Cortes J.E., et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119(5): 1123-1129.
40. Simonsson B, Gedde-Dahl T, Markevärn B, et al.; Nordic CML Study Group. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011; 118(12): 3228-3235.
41. Cortes J, Quintas-Cardama A, Jones D., et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011; 117(3): 572-580.
42. O'Brien S., Abboud CN, Akhtari M, et al., Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, Version 1.2013, National Comprehensive Cancer Network (NCCN). http://www.nccn.org.
43. Kantarjian HM, Giles FJ, Bhalla K.N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117(4): 1141-1145.
44. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013; 27(1): 107-112.
45. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95(2): 232-240.
46. Rea D, Vellenga E, Junghanss C., et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia receiving dasatinib. [abstract] Haematologica. 2012; 97(s1). [Abstract 1430]
47. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011; 118(17): 4567-4576.
48. Khoury HJ, Cortes JE, Kantarjian H.M., et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012; 119(15): 3403-3412.
49. O'Hare T., Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16(5): 401-412.
50. Cortes JE, Kantarjian H, Shah N.P., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367(22): 2075-2088.
51. Cortes J, Kim DW, Pinilla-Ibarz J, et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. [abstract] Blood. 2012; 120(21). [Abstract 163]
52. Kantarjian HM, Kim DW, Pinilla-Ibarz J, et al. Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia: 12-month follow-up of the PACE trial. [abstract] Blood. 2012; 120(21). [Abstract 915]
53. Saussele S, Lauseker M, Gratwohl A., et al.; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010; 115(10). 1880-1885.
54. Warlick E, Ahn KW, Pedersen T.L., et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012; 119(17): 4083-4090.
55. Pavlu J, Szydlo RM, Goldman J.M., Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011; 117(3): 755-763.
56. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(11): 1018-1029. (Pubitemid 47629897)
57. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(12): 1116-1128. (Pubitemid 350182968)
58. Soverini S, Gnani A, Colarossi S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009; 114(10): 2168-2171.
59. Soverini S, Hochhaus A, Nicolini F.E., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011; 118(5): 1208-1215.
60. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011; 25(1): 7-22.
61. Gruber FX, Ernst T, Porkka K., et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia. 2012; 26(1): 172-177.
62. Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013; 121(3): 489-498.
63. Hochhaus A, Saglio G, Larson R.A., et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013; 121(18): 3703-3708.
64. Parker WT, Ho M, Scott H.S., Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012; 119(10): 2234-2238.
65. Smith CC, Brown M, Parker W.T., et al. Single Molecule Real Time (SMRT™) sequencing sensitively detects the evolution of polyclonal and compound BCR-ABL mutations in patients who relapse on kinase inhibitor therapy. [abstract] Blood. 2012; 120(21). [Abstract 917]
66. Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain [published online ahead of print June 21, 2013]. Blood. doi:10.1182/blood-2013-03-487728.
67. Ernst T, Hoffmann J, Erben P., et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2008; 93(9): 1389-1393.
68. Redaelli S, Piazza R, Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009; 27(3): 469-471.
69. Jabbour E, Jones D, Kantarjian H.M., et al. Longterm outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009; 114(10): 2037-2043.
70. Parker WT, Lawrence RM, Ho M, et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol. 2011; 29(32): 4250-4259.
71. O'Hare T., Walters DK, Stoffregen E.P., et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistance ABL kinase domain mutants. Cancer Res. 2005; 65(11): 4500-4505. (Pubitemid 40740783)
72. Peng B, Hayes M, Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004; 22(5): 935-942. (Pubitemid 41103606)
73. Larson RA, Yin OQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012; 68(5): 723-733.
74. Wang X, Roy A, Hochhaus A., Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol. 2013; 5(1): 85-97.
75. Hsyu PH, Mould DR, Upton R.N., Amantea M. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2013; 71(1): 209-218.
76. Cortes JE, Talpaz M, Giles F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003; 101(10): 3794-3800. (Pubitemid 36857848)
77. Milojkovic D, Apperley JF, Gerrard G, et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 2012; 119(8): 1838-1843.
78. Deininger MWN, Cortes J, Paquette R., et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007; 110(7): 1509-1519. (Pubitemid 47463065)
79. Lee SE, Choi SY, Bang J.H., et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012; 205(11): 563-571.
80. Hoffmann VS, Baccarani M, Lindorfer D., et al. Validation of the EUTOS score for prediction of complete cytogenetic response and progression-free survival: application to an independent multicentric series of 1288 patients with chronic myeloid leukeima and review of publications. Leukemia. Prepublished on June 11, 2013,
81. Castagnetti F, Testoni N, Luatti S., et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol. 2010; 28(16): 2748-2754.
82. Marzocchi G, Castagnetti F, Luatti S., et al.; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011; 117(25): 6793-6800.
83. Fabarius A, Leitner A, Hochhaus A., et al.; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011; 118(26): 6760-6768.
84. Luatti S, Castagnetti F, Marzocchi G., et al.; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012; 120(4): 761-767.
85. Verma D, Kantarjian H, Shan J., et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010; 116(11): 2673-2681.
86. Dulucq S, Bouchet S, Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008; 112(5): 2024-2027.
87. McWeeney SK, Pemberton LC, Loriaux M.M., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010; 115(2): 315-325.
88. Jiang X, Forrest D, Nicolini F., et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 2010; 116(12): 2112-2121.
89. White DL, Dang P, Engler J., et al. Functional activity of the OCT-1 protein is predictive of longterm outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010; 28(16): 2761-2767.
90. White DL, Radich J, Soverini S., et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 2012; 97(6): 907-914.
91. Ng KP, Hillmer AM, Chuah CTH, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18(4): 521-528.
92. Angelini S, Soverini S, Ravegnini G., et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013; 98(2): 193-200.
93. Hughes TP, Hochhaus A, Branford S., et al.; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010; 116(19): 3758-3765.
94. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3): 232-238.
95. Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012; 30(35): 4323-4329.
96. Hanfstein B, Müller MC, Hehlmann R., et al.; SAKK; German CML Study Group. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26(9): 2096-2102.
97. Marin D, Hedgley C, Clark R.E., et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with firstline dasatinib. Blood. 2012; 120(2): 291-294.
98. Brummendorf TH, Kantarjian HM, Gambacorti-Passerini C, et al. Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. [abstract] Blood. 2012; 120(21). [Abstract 69]
99. Jain P, Kantarjian HM, Nazha A, et al. Early molecular and cytogenetic response predict for significantly longer event-free survival and overall survival in patients with newly diagnosed chronic myeloid leukemia in chronic phase - an analysis of 4 tyrosine kinase inhibitor modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib). [abstract] Blood. 2012; 120(21). [Abstract 70]
100. Hochhaus A, Hughes TP, Saglio G, et al. Outcome of patients with chronic myeloid leukemia in chronic phase based on early molecular response and factors associated with early response: 4-year follow-up of data from ENESTnd (evaluating nilotinib efficacy and safety in clinical trials newly diagnosed patients). [abstract] Blood. 2012; 120(21). [Abstract 167]
101. Rousselot P, Guilhot J, Preudhomme C., et al. Relationship between molecular responses and disease progression in patients treated first line with imatinib based regimens: impact of treatment arm within the French Spirit trial from the French CML group. [abstract] Blood. 2012; 120(21). [Abstract 168]
102. Saglio G, Kantarjian HM, Shah N, et al. Early response (molecular and cytogenetic), 3-year data and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase: exploratory analysis of DASISION 3-year data. Blood. 2012; 120(21). [Abstract 1675]
103. Neelakantan P, Gerrard G, Lucas C., et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013; 121(14): 2739-2742.
104. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008; 112(3): 516-518.
105. Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009; 113(21): 5058-5063.
106. Milojkovic D, Nicholson E, Apperley J.F., et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2010; 95(2): 224-231.
107. Jabbour E, Kantarjian H, O'Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011; 117(6): 1822-1827.
108. Jabbour E, le Coutre PD, Cortes J, et al. Prediction of outcomes in patients with Ph1 chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013; 27(4): 907-913.
109. Jabbour E, Kantarjian H, Ghanem H., et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013; 13(3): 302-306.
110. Kim S-H, Menon H., Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL tyrosine kinase inhibitors. [abstract] Blood. 2012; 120(21). [Abstract 695]
111. Cortes J, Lipton JH, Rea D, et al.; Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012; 120(13): 2573-2580.
112. Cortes J, Digumarti R, Parikh P.M., et al.; Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013; 88(5): 350-354.
113. Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J. Re-emergence of interferon - a in the treatment of chronic myeloid leukemia. Leukemia. 2013; 27(4): 803-812.
114. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008; 22(12): 2176-2183.
115. Apperley JF, Cortes JE, Kim D.W., et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009; 27(21): 3472-3479.
116. Kantarjian H, Cortes J, Kim D.W., et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009; 113(25): 6322-6329.
117. Giles FJ, Abruzzese E, Rosti G., et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010; 24(7): 1299-1301.
118. Jabbour E, Cortes J, Santos FPS, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011; 117(13): 3641-3647.
119. Jiang Q, Xu LP, Liu D.H., et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011; 117(11): 3032-3040.
120. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011; 118(20): 5697-5700.
121. Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012; 26(5): 959-962.
122. le Coutre P.D., Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph1 chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012; 26(6): 1189-1194.
123. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007; 110(8): 2828-2837. (Pubitemid 350006935)
124. Hehlmann R. How I treat CML blast crisis. Blood. 2012; 120(4): 737-747.
125. Gratwohl A, Hermans J, Goldman J.M., et al.; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998; 352(9134): 1087-1092. (Pubitemid 28448513)
126. Rousselot P, Huguet F, Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109(1): 58-60. (Pubitemid 46053043)
127. Ross DM, Branford S, Seymour J.F., et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010; 24(10): 1719-1724.
128. Mahon FX, Réa D, Guilhot J., et al.; Intergroupe Français des Leucémies Myélöides Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029-1035.
129. Takahashi N, Kyo T, Maeda Y., et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012; 97(6): 903-906.
130. Sobrinho-Simões M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 2010; 116(8): 1329-1335.
131. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011; 118(13): 3657-3660.
132. Chu S, McDonald T, Lin A., et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011; 118(20): 5565-5572.
133. EUROSKI. http://www.clinicaltrials.gov/ct2/show/NCT01596114.
134. Russo D, Martinelli G, Malagola M., et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. Prepublished on May 15, 2013.
135. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica. 2008; 93(2): 161-169.
136. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011; 25(2): 201-210.
137. Rosti G, Castagnetti F, Gugliotta G., Palandri F, Baccarani M. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev. 2012; 38(3): 241-248.
138. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 113(22): 5401-5411.
139. Marin D, Bazeos A, Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14): 2381-2388.
140. Eliasson L, Clifford S, Barber N., Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011; 35(5): 626-630.
141. Efficace F, Baccarani M, Breccia M., et al.; GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011; 118(17): 4554-4560.
142. Efficace F, Baccarani M, Rosti G., et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012; 107(6): 904-909.
143. Efficace F, Baccarani M, Breccia M., et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. Prepublished on Feb 18, 2013.
144. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12(8): 908-916. (Pubitemid 44175142)
145. Quintás-Cardama A., Han X, Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009; 114(2): 261-263.
146. Palandri F, Castagnetti F, Soverini S., et al. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica. 2009; 94(12): 1758-1761.
147. Vandyke K, Fitter S, Dewar A.L., Hughes TP, Zannettino AC. Dysregulation of bone remodeling by imatinib mesylate. Blood. 2010; 115(4): 766-774.
148. Valent P. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica. 2011; 96(10): 1395-1397.
149. Le Coutre P.D., Rea D, Abruzzese E., et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011; 103(17): 1347-1348.
150. Aichberger KJ, Herndlhofer S, Schernthaner G.H., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011; 86(7): 533-539.
151. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011; 86(7): 610-611.
152. Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012; 53(12): 2351-2361.
153. Futosi K, Németh T, Pick R., Vántus T, Walzog B., Mócsai A. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood. 2012; 119(21): 4981-4991.
154. Zarbock A. The shady side of dasatinib. Blood. 2012; 119(21): 4817-4818.
155. Kim TD, le Coutre PD, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. Haematologica. 2012; 97(6): 883-889.
156. Giona F, Mariani S, Gnessi L., et al. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica. 2013; 98(3):e25-e27.
157. Barreto Miranda M., Lauseker M, Proetel U., et al. Secondary malignancies in CML patients - Data from the German CML study IV. [abstract] Blood. 2012; 120(21). [Abstract 3746]
158. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013; 27(6): 1310-1315.
159. Kim TD, Rea D, Schwarz M., et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013; 27(6): 1316-1321.
160. Pfirrmann M, Hochhaus A, Lauseker M., Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011; 25(9): 1433-1438.
161. Guilhot J, Baccarani M, Clark R.E., et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012; 119(25): 5963-5971.
162. Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011; 29(32): 4260-4265.
163. Gurion R, Gafter-Gvili A, Vidal L., et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica. 2013; 98(1): 95-102.
164. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia. 2012; 26(2): 214-224.
165. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012; 119(8): 1821-1830.
166. Pemmaraju N, Kantarjian H, Shan J., et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012; 97(7): 1029-1035.
167. Millot F, Suttorp M, Guilhot J., et al. The international registry for chronic myeloid leukemia in children and adolescents (I-CML-Ped-Study): objectives and preliminary results. [abstract] Blood. 2012; 120(21). [Abstract 3741]
168. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012; 118(12): 3123-3127.
169. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121(22): 4439-4442.